Best Agrolife Ltd. · NSE:BESTAGRO

Best Agrolife — Q2 FY25 Earnings Presentation

20 slides from Best Agrolife's earnings presentation, Oct 21, 2024

  1. Slide 1: Intimation under Regulation 30 - Corporate Presentation

    October 21, 2024 BSE Limited National Stock Exchange of India Limited 25th Floor, P.J. Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Mumbai-400001 Bandra - Kurla Complex Bandra (E), Mumbai-400051 SCRIP CODE: 539660 SCRIP ID: BESTAGRO Sub: Intimation under Regulation 30_Corporate Presentation D

  2. Slide 2: Q2 & H1 FY25 Earnings Presentation

    Q2 & H1 FY25 Earnings Presentation

  3. Slide 3: Disclaimer

    Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i

  4. Slide 4: Table of Contents

    Table of Contents Company Snapshot Management Comment Key Highlights Q2 & H1 FY25 Financial Highlights Way Ahead

  5. Slide 5: Company Snapshot

    Company Snapshot 13th 40 5 Largest Indian Warehouses Patented Products 10,000+ Agrochemical Company* 21 with focus on Branded sales Dealers States 4 27% Manufacturing units 7000 MTPA 494+ 1,150+ 3 Year Revenue CAGR 42% Formulations Technical Capacity Employees registered in India 35,500 KL Formulati

  6. Slide 6: Management Comment

    Management Comment “We are pleased to announce that Best Agrolife Ltd. has delivered a strong performance in Q2 FY25, capitalizing on favourable market conditions and executing our strategic shift toward branded sales. Our commitment to enhancing brand visibility and expanding our market presence ha

  7. Slide 7: Key Highlights

    Key Highlights 01 Enhanced margin performance • Increased EBITDA margins on Y-o-Y basis on account of stability in raw material prices and higher sales of branded products. Gross margins for Q2 FY25 stood at 34%. • The volumes of Branded sales in Q2 FY25 has increased by 35% on Y-o-Y • Revenue from

  8. Slide 8: Financial Highlights

    Financial Highlights Revenue from operations EBITDA* 811 747 147 20% (₹ Crore) (₹ Crore) 144 18% Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 PAT EPS 95 95 13% 40.00 40.00 12% (₹ Crore) (₹ Crore) Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 *EBITDA is calculated excluding other income

  9. Slide 9: Building a Branded Business and focusing on Patented Products

    Building a Branded Business and focusing on Patented Products… Branded v/s Institutional Contribution of Patented Sales products in Branded Sales 37% 35% 38% Ronfen Warden Extra 63% 65% 25% Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 Branded Institutional Sales Patented Defender 44% 36% 36% 35% 56% 64% 64% 21%

  10. Slide 10: Consolidated P&L for Q2 FY25

    Consolidated P&L for Q2 FY25 Value (INR Cr) Q2 FY25 Q2 FY24 Y-o-Y Q1 FY25 Revenue from Operations 747 811 (8)% 519 Other Income 1 (3) 3 Total Revenue 748 808 (8)% 522 Cost of Goods Sold 495 597 391 Employee Benefits Expense 29 19 26 Other Operating Expenses 76 51 47 Total Expenses 600 667 464 EBITDA

  11. Slide 11: Consolidated P&L for H1 FY25

    Consolidated P&L for Q2 FY25 Value (INR Cr) H1 FY25 H1 FY24 FY24 Revenue from Operations 1,266 1,423 1,873 Other Income 4 2 3 Total Revenue 1,270 1,425 1,876 Cost of Goods Sold 886 1026 1415 Employee Benefits Expense 55 35 82 Other Operating Expenses 123 88 151 Total Expenses 1,064 1,149 1,648 EBITD

  12. Slide 12: Consolidated Balance sheet

    Consolidated Balance sheet Value (INR Cr) As on Sept 30, 2024 As on Sept 30, 2023 As on Mar 31, 2024 Equity And Liabilities Share Holders Fund 756 706 647 Non-current Liabilities Long Term Borrowings 18 29 21 Other Financial Liabilities 36 19 41 Total Non-current Liabilities 54 48 62 Current Liabili

  13. Slide 13: Key Ratios

    Key Ratios Debt to Equity (x) Net Debt to Equity (x) 1.06 0.89 0.90 0.97 0.80 0.75 0.68 0.60 FY22 FY23 FY24 H1 FY25 FY22 FY23 FY24 H1 FY25 Current Ratio (x) ROCE 35% 1.36 1.35 30% 26% 30% 25% 1.26 25% 1.21 20% 15% 15% 10% FY22 FY23 FY24 H1 FY25 FY21 FY22 FY23 FY24 *Formulae: ROCE= EBIT/ Capital Empl

  14. Slide 14: Working Capital Movement

    Working Capital Movement 212 186 175 178 167 165 145 140 135 131 121 117 FY23 FY24 H1 FY24 H1 FY25 Inventory Days Cash coversion days Working capital Days 13

  15. Slide 15: Experienced Management Team

    Experienced Management Team Mr. Vimal Alawadhi Mr. P . N. Karlekar Mr. S. B. V. Rama Prasad Mr. N Surendra Sai Mr. Vikas Jain Managing Director Managing Director Executive Director Head International Business Chief Financial Officer A true v isio na ry a nd a pa s sion ate A c he m ic a l Eng ine er

  16. Slide 16: Glimpse of Differentiated Products

    Glimpse of Differentiated Products CITIGEN VISTARA RONFEN (C T P R) TRICOLOR TOMBO (C T P R) Patented Product (TEMBOTRIONE) Patented Product First to launch in India after Innovator Launched Launched Launched Launched  A single shot solution that controls  A new generation corn  Best Agrolife is

  17. Slide 17: Glimpse of Differentiated Products

    Glimpse of Differentiated Products AZARO (PYROXASULFONE) PROPIQUE NEMAGEN DEFENDER (PROPIQUAZAFOP) WARDEN EXTRA ORISULAM 9Patented (3) Registration Product Patented Product Patented Product Patented Product Patented Product Launched Launched Launched Launched Launched Launched  Novel pre-emergence

  18. Slide 18: Patented Products Launch Plan FY25

    Patented Products Launch Plan FY25 Patented Product Patented Product CYAZOFAMID + DIMETHOMORPH + HALOXYFOP + IMAZETHAPYR + DIFENOCONAZOLE CHLORIMURON HERBICIDE FUNGICIDE To be launched To be launched  Patent for herbicidal Composition of  Composition of Cyazofamid, Haloxyfop + Imazethapyr + Dimeth

  19. Slide 19: Outlook For FY25

    Outlook For FY25 Launch of new & Innovative products with higher margins Ramping up distribution & branded products business Revenue Growth 15 to 20% EBITDA Margin 15 to 17% Improving Cash Flows Improving working capital cycle

  20. Slide 20: Thank You

    Thank You For queries please contact Adfactors PR Contact US Savli Mangle ir@bestagrolife.com savli.mangle@adfactorspr.com (Investor Relations) Samruddhi Bane Samruddhi.bane@adfactorspr.com Contact: +91 9619624264 DIS CLAIME R This presentation includes certain forward looking statements and informa

Best Agrolife — Q2 FY25 Earnings Presentation on 6ix